Mel-CAM Antibody (3H1869): sc-71564

Mel-CAM Antibody (3H1869) is a mouse monoclonal IgG1 antibody that detects Mel-CAM in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Mel-CAM, also known as MCAM, MUC18, or CD146, is a transmembrane glycoprotein encoded by the human Mel-CAM gene, which plays a crucial role in cell adhesion and is a member of the immunoglobulin superfamily. This protein consists of 603 amino acids, featuring a signal peptide, five immunoglobulin-like domains, a transmembrane region, and a short cytoplasmic tail, which are essential for its function. Mel-CAM is predominantly expressed in advanced primary and metastatic melanomas, as well as in neuroectodermal lineage cell lines, but is absent in normal melanocytes. Notably, Mel-CAM is present in approximately 80% of advanced primary human melanomas and is closely associated with the progression of metastatic disease. The activation of Mel-CAM triggers an outside-in signaling pathway involving protein tyrosine kinases such as Fyn, Focal Adhesion Kinase (FAK), and paxillin, which are vital for cellular communication and adhesion. Furthermore, Mel-CAM significantly influences the dynamics of actin cytoskeleton rearrangement, which is critical for maintaining thymic architecture and function, highlighting its importance in both tumor biology and immune system integrity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Mel-CAM Antibody (3H1869) References:

1. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication.  |  Satyamoorthy, K., et al. 2001. Oncogene. 20: 4676-84. PMID: 11498790
2. Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor.  |  Guezguez, B., et al. 2007. J Immunol. 179: 6673-85. PMID: 17982057
3. Akt and PI3K-dependent but CREB-independent upregulation of MCAM by endothelin-3 in human melanocytes.  |  Williams, B., et al. 2014. Melanoma Res. 24: 404-7. PMID: 24743054
4. MCAM knockdown impairs PPARγ expression and 3T3-L1 fibroblasts differentiation to adipocytes.  |  Gabrielli, M., et al. 2018. Mol Cell Biochem. 448: 299-309. PMID: 29468504
5. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus.  |  Breuer, J., et al. 2018. J Neuroinflammation. 15: 236. PMID: 30134924
6. Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis.  |  Petersen, ER., et al. 2019. J Neuroimmunol. 337: 577085. PMID: 31655423
7. MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy.  |  Rapanotti, MC., et al. 2021. Int J Mol Sci. 22: PMID: 34830300
8. Intestinal epithelium-specific Fut2 deficiency promotes colorectal cancer through down-regulating fucosylation of MCAM.  |  Wang, W., et al. 2023. J Transl Med. 21: 82. PMID: 36739428
9. Targeting MCAM for next-generation modulation of leucocyte trafficking.  |  Schneider-Hohendorf, T. and Wiendl, H. 2023. Brain. 146: 1236-1237. PMID: 36946303
10. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand.  |  Johnson, JP., et al. 1997. Int J Cancer. 73: 769-74. PMID: 9398060

The preferred Mel-CAM antibody is Mel-CAM Antibody (P1H12): sc-18837.